Cryosite Limited provided earnings guidance for the year ended June 30, 2018. Based on non-audited management accounts for the year ended 30 June 2018, and before the normal year-end review of the carrying value of assets, the company expects to report a full year loss after tax in the range of $1.2 million - $1.3 million. The loss was principally due to the write downs and one off expenses that occurred in the first half of the year relating to the closure of the processing and collection of cord blood and tissue component of the Company's business. The company continued to trade with a positive cashflow from operations for the full year. This was offset by an investment in infrastructure resulting in a net cash outflow for the year of $400,000. The above assessment is subject to audit and the normal year-end review of the carrying value of assets.